Amylyx Pharmaceuticals Appoints New Board Member for 2025 Term
Company Announcements

Amylyx Pharmaceuticals Appoints New Board Member for 2025 Term

Amylyx Pharmaceuticals Inc (AMLX) has provided an announcement.

Amylyx Pharmaceuticals, Inc. has strengthened its Board of Directors by bringing on Bernhardt Zeiher, MD, as a Class I director, with his term extending to the 2025 annual stockholders’ meeting. His extensive industry experience includes a prominent tenure as Chief Medical Officer at Astellas Pharma and participation in several influential boards. Zeiher steps into a role on the Nominating and Corporate Governance Committee, succeeding Paul Fonteyne, and is set to receive a comprehensive compensation package including annual retainers and stock options under the company’s Non-Employee Director Compensation Policy.

See more data about AMLX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAmylyx price target raised to $12 from $8 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskAmylyx Pharmaceuticals Q3 2024 Financial Highlights
TheFlyAmylyx reports Q3 EPS ($1.07), consensus (71c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App